Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis

Medical Mycology

Volumn 45, Issue 8, 2007, Pages 691-700

  Jawhara, Samir ^a   Poulain, Daniel ^a  

^a INSERM   (France)

Author keywords

Candida albicans; Dextran sulphate sodium; Inflammation; Saccharomyces boulardii

Indexed keywords

ALPHA INTERFERON; CYTOKINE; DEXTRAN SULFATE; MESSENGER RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANDIDA ALBICANS; COLITIS; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; FUNGAL COLONIZATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SACCHAROMYCES BOULARDII; SCORING SYSTEM;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; COLITIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FECES; INTERFERON TYPE II; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SACCHAROMYCES; STATISTICS, NONPARAMETRIC; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANDIDA ALBICANS; MUS; SACCHAROMYCES BOULARDII;

EID: 36348965867     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780701523013     Document Type: Article

References (57)

1. Bodey, GP. (1984) Candidiasis in cancer patients. Am J Med, 77, pp. 13-19.
2. Davies, AN, Brailsford, SR and Beighton, D. (2006) Oral candidosis in patients with advanced cancer. Oral Oncol, 42, pp. 698-702.
3. Myerowitz, RL, Pazin, GJ and Allen, CM. (1977) Disseminated candidiasis. Changes in incidence, underlying diseases, and pathology. Am J Clin Pathol, 68, pp. 29-38.
4. Verghese, A., Prabhu, K., Diamond, RD and Sugar, A. (1988) Synchronous bacterial and fungal septicemia. A marker for the critically ill surgical patient. Am Surg, 54, pp. 276-283.
5. de Repentigny, L., Phaneuf, M. and Mathieu, LG. (1992) Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice. Infect Immun, 60, pp. 4907-4914.
6. Calderone, R. (2002) Candida and Candidiasis, Washington, DC
7. Cole, GT, Halawa, AA and Anaissie, EJ. (1996) The role of the gastrointestinal tract in hematogenous candidiasis: From the laboratory to the bedside. Clin Infect Dis, 22, p. S73.
8. Stone, HH, Geheber, CE, Kolb, LD and Kitchens, WR. (1973) Alimentary tract colonization by Candida albicans. J Surg Res, 14, pp. 273-276.
9. Czerucka, D. and Rampal, P. (2002) Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect, 4, pp. 733-739.
10. Buts, JP and De Keyser, N. (2006) Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci, 51, pp. 1485-1492.
11. Vidon, N., Huchet, B. and Rambaud, JC. (1986) [Influence of Saccharomyces boulardii on jejunal secretion in rats induced by cholera toxin]. Gastroenterol Clin Biol, 10, pp. 13-16.
12. Massot, J., Desconclois, M. and Astoin, J. (1983) [Protection by Saccharomyces boulardii against Escherichia coli diarrhea in newborn mice]. Ann Pharm Fr, 40, pp. 445-449.
13. Elmer, GW and Corthier, G. (1991) Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol, 37, pp. 315-317.
14. Algin, C., Sahin, A., Kiraz, N., Sahinturk, V. and Ihtiyar, E. (2005) Effectiveness of bombesin and Saccharomyces boulardii against the translocation of Candida albicans in the digestive tract in immunosuppressed rats. Surg Today, 35, pp. 869-873.
15. Guslandi, M., Mezzi, G., Sorghi, M. and Testoni, PA. (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci, 45, pp. 1462-1464.
16. Guslandi, M., Giollo, P. and Testoni, PA. (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol, 15, pp. 697-698.
17. Standaert-Vitse, A., Jouault, T. and Vandewalle, P. (2006) Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology, 130, pp. 1764-1775.
18. Gillum, AM, Tsay, EY and Kirsch, DR. (1984) Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet, 198, pp. 179-182.
19. Sendid, B., Francois, N. and Standaert, A. (2007) Prospective evaluation of the new chromogenic medium CandiSelect 4 for differentiation and presumptive identification of the major pathogenic Candida species. J Med Microbiol, 56, pp. 495-499.
20. Nishiyama, Y., Aoki, Y. and Yamaguchi, H. (1995) Morphological aspects of cell wall formation during protoplast regeneration in Candida albicans. J Electron Microsc (Tokyo), 44, pp. 72-78.
21. Hartmann, G., Bidlingmaier, C. and Siegmund, B. (2000) Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther, 292, pp. 22-30.
22. Odds, FC. (1988) Candida and Candidosis, Bailliere Tindall, Philadelphia
23. Voss, A., Hollis, RJ, Pfaller, MA, Wenzel, RP and Doebbeling, BN. (1994) Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol, 32, pp. 975-980.
24. Nucci, M. and Anaissie, E. (2001) Revisiting the source of candidemia: skin or gut?. Clin Infect Dis, 33, pp. 1959-1967.
25. Bille, J. (1995) [Systemic mycotic infections: Epidemiology and diagnostic criteria]. Schweiz Med Wochenschr, 125, pp. 1123-1129.
26. Martin, GS, Mannino, DM, Eaton, S. and Moss, M. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 348, pp. 1546-1554.
27. Olaechea, PM, Palomar, M. and Leon-Gil, C. (2004) Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis, 23, pp. 323-330.
28. Ducluzeau, R. and Bensaada, M. (1982) [Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice]. Ann Microbiol (Paris), 133, pp. 491-501.
29. Brugier, S. and Patte, F. (1975) Antagonisme in vitro entre l'Ultra-levure et différents germes bacteriens. Méd Paris, 45, pp. 3-8.
30. Shanahan, F. (2002) Crohn's disease. Lancet, 359, pp. 62-69.
31. Shanahan, F. (2000) Nutrient tasting and signaling mechanisms in the gut V. Mechanisms of immunologic sensation of intestinal contents. Am J Physiol Gastrointest Liver Physiol, 278, p. G191.
32. Buts, JP. (1999) Mechanisms of action of biotherapeutic agents, Humana Press, Totowa, NJ
33. Buts, JP, Bernasconi, P., Vaerman, JP and Dive, C. (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci, 35, pp. 251-256.
34. Hennequin, C., Thierry, A. and Richard, GF (2001) Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol, 39, pp. 551-559.
35. Maillée, PVN M., Bertout, S., Vaillant, C. and Bastide, JM. (2001) Genotypic study of Saccharomyces boulardii compared to the Saccharomyces sensu stricto complex species. J Mycol Med, 11, pp. 19-25.
36. Fietto, JL, Araujo, RS and Valadao, FN (2004) Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can J Microbiol, 50, pp. 615-621.
37. Castagliuolo, I., LaMont, JT, Nikulasson, ST and Pothoulakis, C. (1996) Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun, 64, pp. 5225-5232.
38. Zwolinska-Wcislo, M., Budak, A. and Trojanowska, D. (2006) [The influence of Candida albicans on the course of ulcerative colitis]. Przegl Lek, 63, pp. 533-538.
39. Nagy, F., Szenasi, Z., Szollosy, E., Kiss, I. and Varro, V. (1989) Determination and kinetics of antibody response to Candida albicans in ulcerative colitis. Hepatogastroenterology, 36, pp. 182-184.
40. Kalkanci, A., Tuncer, C. and Degertekin, B. (2005) Detection of Candida albicans by culture, serology and PCR in clinical specimens from patients with ulcerative colitis: Re-evaluation of an old hypothesis with a new perspective. Folia Microbiol (Praha), 50, pp. 263-267.
41. Joossens, S., Suenaert, P., Noman, M., Vermeire, S. and Rutgeerts, P. (2005) Saccharomyces boulardii in Crohn's disease: Effect on anti-Saccharomyces cerevisiae antibodies and intestinal permeability. Inflamm Bowel Dis, 11, pp. 863-864.
42. Sun, FF, Lai, PS and Yue, G. (2001) Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation, 25, pp. 33-45.
43. Murano, M., Maemura, K. and Hirata, I. (2000) Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol, 120, pp. 51-58.
44. Reed, KL, Fruin, AB and Gower, AC (2005) NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci, 50, pp. 2366-2378.
45. Sougioultzis, S., Simeonidis, S. and Bhaskar, KR (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun, 343, pp. 69-76.
46. Dahan, S., Dalmasso, G. and Imbert, V. (2003) Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun, 71, pp. 766-773.
47. Dalmasso, G., Cottrez, F. and Imbert, V. (2006) Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology, 131, pp. 1812-1825.
48. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. and Medzhitov, R. (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell, 118, pp. 229-241.
49. Netea, MG, Van Der Graaf, CA and Vonk, AG (2002) The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis, 185, pp. 1483-1489.
50. Thoma-Uszynski, S., Stenger, S. and Takeuchi, O. (2001) Induction of direct antimicrobial activity through mammalian toll-like receptors. Science, 291, pp. 1544-1547.
51. Netea, MG, Sutmuller, R. and Hermann, C. (2004) Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol, 172, pp. 3712-3718.
52. Hoag, KA, Street, NE, Huffnagle, GB and Lipscomb, MF. (1995) Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol, 13, pp. 487-495.
53. Hsieh, CS, Macatonia, SE, O'Garra, A. and Murphy, KM. (1995) T cell genetic background determines default T helper phenotype development in vitro. J Exp Med, 181, pp. 713-721.
54. Huffnagle, GB, Boyd, MB, Street, NE and Lipscomb, MF. (1998) IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol, 160, pp. 2393-2400.
55. Liu, T., Matsuguchi, T., Tsuboi, N., Yajima, T. and Yoshikai, Y. (2002) Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infect Immun, 70, pp. 6638-6645.
56. Berg, R., Bernasconi, P., Fowler, D. and Gautreaux, M. (1993) Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. J Infect Dis, 168, pp. 1314-1318.
57. Herrero, E., de la Torre, MA and Valentin, E. (2003) Comparative genomics of yeast species: New insights into their biology. Int Microbiol, 6, pp. 183-190.